Industry & Policy News

[Amgen] Amgen announced the US FDA has approved BLINCYTO® for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of measurable residual disease status.

[Multiple Sclerosis News Today] The National Institute of Neurological Disorders and Stroke has awarded a $2.9 million, five-year grant to a research project that aims to advance a new technology that could improve stem cell therapies for multiple sclerosis (MS) and other neurological disorders.

[Seraxis (Newswire)] Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund that aims to foster Maryland research to enhance and propel stem cell treatments.

[Healio] The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.

[Fortune] Senator Bernie Sanders dropped his pursuit of a subpoena for a top pharmaceutical executive after the company’s CEO agreed to testify before the Senate later this year.

Cranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, announced the US FDA approved the Abbreviated New Drug Application for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment...